Taltorvic (ridaforolimus) / Takeda, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 80 Diseases   2 Trials   2 Trials   151 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
ACTRN12608000214336: A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bone Sarcomas.

Recruiting
3
650
 
ARIAD Pharmaceuticals, Inc., ARIAD Pharmaceuticals, Inc.
Metastatic soft tissue or bone sarcomas
 
 
2011-003433-33: A Single Dose Study to Assess the Biocomparison of MK-8669 in Subjects

 
1
21
NA
ridaforolimus, MK-8669,
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Sarcoma
 
 

Download Options